MicroPort Scientific, a developer, manufacturer and operator of intervention products for the treatment of vascular diseases, led a $43m Series C funding round of Robocath, a designer and developer of cardiovascular robotic systems. Zhejiang Silk Road Fund, TUS-Holdings, CS Group and Anaxago also participated in the round. “This financial round gives Robocath the resources to achieve its overall ambitions. MicroPort’s commitment demonstrates the relevance of our value proposition. Thanks to the excellent technological and commercial synergies between our companies, we will accelerate our development and together build a great future in the vascular robotic field. This will benefit patients, physicians and ultimately healthcare systems,” Lucien Goffart, Robocath CEO.